EC Pharmacology And Toxicology

Research Article Volume 12 Issue 9 - 2024

Enhancement of Temozolomide Cytotoxicity against Human Glioblastoma by Silver and Titanium Nanoparticles

Sakshi Goswami, Yeshvandra Verma and S V S Rana*

Department of Toxicology, Ch. Charan Singh University, Meerut, India
*Corresponding Author: S V S Rana, Professor Emeritus, Department of Toxicology, Ch Charan Singh University, Meerut, India.
Received: July 30, 2024; Published: September 13, 2024



Temozolomide (TMZ), an antineoplastic drug, is the first line chemotherapeutic agent approved by FDA to treat human glioblastoma (GBM), a malignant tumor of central nervous system. However, a strategy of combined treatment of TMZ and nanoparticles has emerged as a novel approach to treat GBM. During present investigations, combined effects of TMZ, silver and titanium nanoparticles have been studied on GBM employing cytotoxicity parameters. Nanoparticles were characterized using a couple of methods. IC50 values of these agents were calculated following OECD guidelines. Human GBM cell line - U87MG were cultured under laboratory conditions. The cell were separated into different groups and exposed to different concentrations ranging from 200 µM - 600 µM of AgNPs, 12.5 µM - 100.12 µM of TiO2NPs and 200 µM - 600 µM of TMZ with MEM for 24h at 37°C and 5% CO2 atmosphere. Thereafter, cytotoxicity amongst different groups of GBM was monitored through - trypan blue exclusion method, MTT assay and cell proliferation assay. The results showed a dose dependent effect of TMZ on cell mortality. Cytotoxicity was enhanced by combined treatments of TMZ and NPs. However, better effects were registered in GBM treated with TMZ+AgNPs than TMZ+TiO2NPs. The cytotoxic effect has been attributed to reactive oxygen species generated by NPs. Further, the roles of enhanced permeability and retention (EPR) mechanism and nanoparticle induced epithelial cell leakiness (NanoEL) have also been discussed. In brief, present study suggests that a strategy of combined treatment with TMZ and NPs yields better antitumor results.

 Keywords: Temozolomide; Glioblastoma; Silver Nanoparticles; Titanium Nanoparticles; Cytotoxicity

  1. Verhaak RGW., et al. “Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PGDFRA, IDH1, EGFR and NF1”. Cancer Cell1 (2010): 98-110.
  2. Alcantara Llaguno SR., et al. “Adult lineage-restricted CNS progenitors specify distinct glioblastoma subtypes”. Cancer Cell4 (2015): 429-440.
  3. Broekman ML., et al. “Multidimensional communication in the microenvirons of glioblastoma”. Nature Reviews Neurology 8 (2018): 482-495.
  4. Tan AC., et al. “Management of glioblastoma: State of the art and future directions”. CA: A Cancer Journal for Clinicians 4 (2020): 299-312.
  5. Peer D., et al. “Nanocarriers as an emerging platform for cancer therapy”. Nature Nanotechnology 2 (2007): 751-760.
  6. Asharani PV., et al. “Antiproliferative activity of silver nanoparticles”. BMC Cell Biology 10 (2009): 65.
  7. Fuster E., et al. “Titanium dioxide, but not zinc oxide nanoparticles cause severe transcriptomic alterations in T98G human glioblastoma cells”. International Journal of Molecular Sciences 4 (2021): 2084.
  8. Osman IF., et al. “Genotoxicity and cytotoxicity of zinc oxide and titanium oxide in HEp-2 cells”. Nanomedicine (London)8 (2010): 1193-1203.
  9. Ribatti D. “The chick embryo chorioallantoic membrane as a model for tumor biology”. Experimental Cell Research 2 (2014): 314-324.
  10. Mavani K and Shah M. “Synthesis of silver nanoparticles by using sodium borohydride as a reducing agent”. International Journal of Engineering Research & Technology (IJERT)3 (2013).
  11. OECD, OECD series on testing and assessment 2014. Number 211. Guidance document for describing non-guideline in vitro test methods. ENV/JM/MONO(2014)35.
  12. Strober W. “Trypan blue exclusion test of cell viability”. Current Protocols in Immunology Appendix 3 (2001): Appendix 3B.
  13. Plumb JA. “Cell sensitivity assays: the MTT assay”. Methods in Molecular Medicine 88 (2004): 165-169.
  14. Mosmann T. “Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays”. Journal of Immunological Methods 1-2 (1983): 55-63.
  15. Jordan RA and Schenkman JB. “Relationship between malondialdehyde production and arachidonate consumption during NADPH-supported microsomal lipid peroxidation”. Biochemical Pharmacology7 (1982): 1393-1400.
  16. Kruger NJ. “The Bradford method for protein quantitation”. The protein protocols handbook (2009): 17-24.
  17. Ellman GL. “Tissue sulfhydryl groups”. Archives of Biochemistry and Biophysics1 (1959): 70-77.
  18. Nam JY and de Groot JF. “Treatment of glioblastoma”. Journal of Oncology Practice 10 (2017): 629-638.
  19. Denny BJ., et al. “NMR and molecular modeling investigation of the mechanism of activation of the anti-tumor drug temozolomide and its interaction with DNA”. Biochemistry31 (1994): 9045-9051.
  20. Roos WP., et al. “Apoptosis in malignant glioma cells triggered by the telozolomide induced DNA lesion O6 methyl guanine”. Oncogene2 (2007): 186-197.
  21. Fan CH., et al. “O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas”. Cell Death and Disease 10 (2013): e876.
  22. Jeyraj M., et al. “Biogenic silver nanoparticles for cancer treatment: an experimental report”. Colloids and Surfaces B: Biointerfaces 106 (2013): 86-92.
  23. Locatelli E., et al. “Targeted delivery of silver nanoparticles and alisertib: in vitro and in vivo synergistic effect against glioblastoma”. Nanomedicine (London) 6 (2014): 839-849.
  24. Kundu M., et al. “pH responsive and targeted delivery of curcumin via phenylboronic acid-functionalized ZnO nanoparticles for breast cancer therapy”. Journal of Advanced Research 18 (2019): 161-172.
  25. Liang P., et al. “Silver nanoparticles enhance the sensitivity of temozolomide on human glioma cells”. Oncotarget 5 (2017): 7533-7539.
  26. Kovacs D., et al. “Cancer therapy by silver nanoparticles: fiction or reality”. International Journal of Molecular Sciences 2 (2022): 839-865.
  27. Kalyane D., et al. “Employment of enhanced permeability and retention effect (EPR): Nanoparticle based prescision tools for targeting of therapeutic and diagnostic agent in cancer”. Materials Science and Engineering 98 (2019): 1252-1276.
  28. Hasse H., et al. “Impact of silver nanoparticles and silver ions on innate immune cells”. Journal of Biomedical Nanotechnology 6 (2014): 1146-1156.
  29. Rana SVS. “Metals and apoptosis: recent developments”. Journal of Trace Elements in Medicine and Biology 4 (2008): 262-284.
  30. Yu Z., et al. “Reactive oxygen species - related nanoparticle toxicity in the biomedical field”. Nanoscale Research Letters 1 (2020): 115-129.
  31. Shukla RK., et al. “TiO2 nanoparticles induce oxidative DNA damage and apoptosis in human liver cell”. Nanotoxicology1 (2013): 48-60.
  32. Wang Y., et al. “Cytotoxicity, DNA damage and apoptosis induced by titanium dioxide nanoparticles in human non-small lung cancer A549 cells”. Environmental Science and Pollution Research International 7 (2014): 5519-5530.
  33. Brandao F., et al. “Genotoxicity of TiO2 nanoparticles in four different human cell lines (A549, HEPG2, A172 and SH-SY5Y)”. Nanomaterials3 (2020): 412.
  34. Marquez-Ramirez SG., et al. “Titanium dioxide nanoparticles inhibit proliferation and induce morphological changes and apoptosis in glial cells”. Toxicology 2-3 (2012): 146-156.
  35. Kenzaoui BH., et al. “Induction of oxidative stress, lysosome activation and autophagy by nanoparticles in human brain derived endothelial cells”. Biochemical Journal 3 (2012): 813-821.
  36. Xue C., et al. “Nano titanium dioxide induces the generation of ROS and potential damage in HaCaT cells under UVA irradiation”. Journal of Nanoscience and Nanotechnology 12 (2010): 8500-8507.
  37. Long TC., et al. “Titanium dioxide (P25) produces reactive oxygen species in immortalized brain microglia (BV2): implications for nanoparticle toxicity”. Environmental Science and Technology 14 (2006): 4346-4352.
  38. Liao F., et al. “The size dependent genotoxic potential of titanium dioxide nanoparticles to endothelial cells”. Environmental Toxicology 11 (2019): 1199-1207.
  39. Brzoska K., et al. “Silver nanoparticles induced changes in DNA methylation and histone H3 methylation in a mouse model of breast cancer”. Materials (Basel)11 (2023): 4163.
  40. Maki A., et al. “Silver nanoparticles induce DNA hypomethylation through proteosome mediated degradation of DNA methyltransferase 1”. Biological and Pharmaceutical Bulletin 12 (2020): 1924-1930.
  41. Malakootian M., et al. “Effect of titanium dioxide nanoparticles on DNA methylation of human peripheral blood mononuclear cells”. Toxicology Research 5 (2021): 1045-1051.
  42. Pogribna M., et al. “Effect of titanium dioxide nanoparticles on DNA methylation in multiple human cell lines”. Nanotoxicology4 (2020): 534-553.
  43. Isakoff WH., et al. “Low-dose continuous 5-fluorouracil combined with leucovorib, nabpaclitaxel, oxaliplatin and bevacizumab for patients with advanced pancreatic cancer: a retrospective analysis”. Targeted Oncology 4 (2018): 461-468.

S V S Rana., et al. “Enhancement of Temozolomide Cytotoxicity against Human Glioblastoma by Silver and Titanium Nanoparticles” ”. EC Pharmacology and Toxicology  12.9 (2024): 01-19.

ECronicon Journal

Our Services

Quick Links

Information

Creative Commons LicenseOpen Access by ECronicon is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at www.ecronicon.net